It is evident that glioblastomas exhibit molecular heterogeneity involving EGFRvIII and PTEN mutations, increased AKT activation, or MGMT promoter methylation that may differentiate the efficiency of EGFR-AKT-mTOR cascade targeting among patients. The gene discussed is AKT1; the disease is glioblastoma.